Skip to main content
. Author manuscript; available in PMC: 2024 Sep 1.
Published in final edited form as: Eur Urol. 2023 Jun 29;84(3):331–340. doi: 10.1016/j.eururo.2023.05.031

Fig. 4 – Landmark analysis of outcomes by achievement of NED. Kaplan-Meier estimates for (A, B) OS, (C, D) MFS, and (E, F) PCSS by NED achieved at (A, C, E) 3 yr or at (B, D, F) 4 yr of treatment.

Fig. 4 –

Shading represents 95% confidence interval. MFS = metastasis-free survival; NED = no evidence of disease; OS = overall survival; PCSS = prostate cancer-specific survival.